Published on : Nov 19, 2018
Albany, New York, November 19, 2018: Triggered by prolonged exposure to hazardous gases such as cigarette smoke and factory emissions, chronic obstructive pulmonary disease (COPD) is a chronic lung disease, characterized by breathlessness. COPD exhibits substantial occurrences across the globe, however complete cure is yet to be attained owing to under developed therapeutics. Several pharmaceutical companies as well as research institutes are thus engaged in apt therapeutics development for enhanced COPD management. This recent business intelligence report titled, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2018' collated in the burgeoning online data archive of Market Research Hub (MRH) analyses pipeline therapeutics as well as future growth scope.
In the light severity and frequency of chronic obstructive pulmonary disease (COPD), pharmaceutical companies are encouraged to execute clinical trials to augment progress in the development of COPD therapeutics development. Additionally, premiere research institutes in association with pharmaceutical companies are also carrying out detailed research activities to attain relevant breakthroughs in chronic obstructive pulmonary disease (COPD) management and therapeutics.
FDA Approves Boehringer Ingelheim’s New Drug for Chronic Obstructive Pulmonary Disease (COPD)
In a recent development in COPD drug development, Boehringer Ingelheim receives FDA approval for its new drug, Stiolto Respimat based on dual therapy mechanisms of tiotropium bromide and olodaterol. Favorable results of prolonged clinical trials affirmed the efficacy of tiotropium in significantly reducing frequent episodes of chronic obstructive pulmonary disease (COPD) amongst adults. The drug is observed to not only enhance airflow in lungs but also relatively decrease exacerbations. This development is expected to steer growth in drug development of COPD, besides positioning Boehringer Ingelheim’s position amidst fierce competition.
Further, as the report progresses, readers are provided with an overview of market segments and factors that impact COPD therapeutics development. This section of the report identifies therapeutics development and therapeutics assessment as prominent market segments in COPD therapeutics pipeline. Based on therapeutics developments, COPD pipeline is identifies products under companies and products under universities and institutes as core segments. In terms of therapeutics assessment, chronic obstructive pulmonary disease (COPD) therapeutics pipeline demonstrates mechanism of action, route of administration, and molecule type as core segments.
Competitive Landscape: Chronic Obstructive Pulmonary Disease (COPD) Pipeline
This exhaustive research report further lends in-depth overview of potential market players in COPD therapeutics development market. The report aims to enhance readers’ perspectives and understanding on COPD therapeutics development market to encourage lucrative business investments for heightened return on investments. Additionally, the report also gauges the efficacy of marketing tactics and tools in driving growth and adoption, focusing on product development milestones, dormant and discontinued projects. Some of the noted market participants benchmarked in chronic obstructive pulmonary disease (COPD) therapeutics development landscape include, AB Science SA, AstraZeneca Plc, Boehringer Ingelheim GmbH, Celon Pharma SA, and Daiichi Sankyo Co Ltd. amongst others.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1931657
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org